LONDON, 7 November 2007 - Lawyers from the London office of Morrison & Foerster MNP have advised Oxford Immunotec, the fully integrated T-cell diagnostics company, on a $40 million financing.  This is the largest financing round for 2 years for a European diagnostics company, according to Dow Jones Venture Source database.  

The funding will be used by Oxford Immunotec to prepare for the launch of its lead product, T-SPOT®. TB, into the U.S., the world's largest diagnostics market.  T-SPOT®. TB is an in vitro T-cell measurement assay used for diagnosing tuberculosis (TB) and latent tubercular infection.  The specific blood test gives a result every time and offers unrivalled and maintained sensitivity in high-risk and immuncompromised patient groups.  The product is already marketed in Europe, Canada and more than 40 other countries worldwide.

The Morrison & Foerster team included James Gubbins, Bradley Theobald, Sophie McGrath, Georgie Shmuel and Matthew Bennett.  Morrison & Foerster began representing the company in 2006, after participating in a formal selection process.

The financing was co-led by new investors Clarus Ventures, Wellington Partners and National Technology Enterprises Company.  Oxford Immunotec's third financing round was also supported by current investors, Prelude Trust, Quester and the Dow Chemical Company.